| Literature DB >> 28108514 |
Lucy Mathot1, Snehangshu Kundu1, Viktor Ljungström1, Jessica Svedlund2, Lotte Moens1, Tom Adlerteg1, Elin Falk-Sörqvist1, Verónica Rendo1, Claudia Bellomo3, Markus Mayrhofer4, Carme Cortina5, Magnus Sundström1, Patrick Micke1, Johan Botling1, Anders Isaksson4, Aristidis Moustakas3, Eduard Batlle5, Helgi Birgisson6, Bengt Glimelius1, Mats Nilsson1,2, Tobias Sjöblom7.
Abstract
The contribution of somatic mutations to metastasis of colorectal cancers is currently unknown. To find mutations involved in the colorectal cancer metastatic process, we performed deep mutational analysis of 676 genes in 107 stages II to IV primary colorectal cancer, of which half had metastasized. The mutation prevalence in the ephrin (EPH) family of tyrosine kinase receptors was 10-fold higher in primary tumors of metastatic colorectal than in nonmetastatic cases and preferentially occurred in stage III and IV tumors. Mutational analyses in situ confirmed expression of mutant EPH receptors. To enable functional studies of EPHB1 mutations, we demonstrated that DLD-1 colorectal cancer cells expressing EPHB1 form aggregates upon coculture with ephrin B1 expressing cells. When mutations in the fibronectin type III and kinase domains of EPHB1 were compared with wild-type EPHB1 in DLD-1 colorectal cancer cells, they decreased ephrin B1-induced compartmentalization. These observations provide a mechanistic link between EPHB receptor mutations and metastasis in colorectal cancer. Cancer Res; 77(7); 1730-40. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28108514 DOI: 10.1158/0008-5472.CAN-16-1921
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701